Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
How does the InBody scan fit into GLP-1 training
For pharma stakeholders, the message is clear: the obesity and diabetes drug market is not just a therapeutic opportunity, but a strategic growth engine for the next decade.
Factors influencing patients to choose one obesity treatment over another: a qualitative study
A.et al (2020)
Although these findings have generated considerable interest, most of the available evidence comes from laboratory and animal studies rather than large human clinical trials
Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself
US$ 29.29
US$ 22.18
US$ 20.65
US$ 22.24
US$ 26.68
US$ 29.64
US$ 24.69
US$ 28.96
